Company intelligence / Profile preview
Allsino Pharmaceutical
- Ownership
- Private
- Employees
- ~2000
- Development stage
- Commercial
Overview
Allsino/Sinopep-Allsino has developed over 400 projects across multiple therapeutic areas. Its clinical pipeline includes synthetic peptides such as semaglutide for obesity (Phase 3) and other programs at IND or preclinical stages. The company also produces APIs and GMP intermediates at commercial scale for global markets including the US, Europe, and Japan. It maintains long-term partnerships with major pharmaceutical companies like Eli Lilly and Merck & Co.
- Therapeutic areas
- OncologyMetabolic DisordersEndocrinologyPsychiatryInfectious Diseases
- Modalities
- Small moleculeSynthetic peptideOligonucleotide
- Industry
- Biotech
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →Partnerships
Beyond the preview
Go deeper on Allsino Pharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Allsino Pharmaceutical.